215 related articles for article (PubMed ID: 21545608)
1. A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog').
Raffa RB
J Clin Pharm Ther; 2011 Jun; 36(3):257-9. PubMed ID: 21545608
[TBL] [Abstract][Full Text] [Related]
2. Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.
Raffa RB; Tallarida RJ
J Clin Pharm Ther; 2010 Jun; 35(3):249-55. PubMed ID: 20831527
[TBL] [Abstract][Full Text] [Related]
3. Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment).
Raffa RB
J Clin Pharm Ther; 2013 Aug; 38(4):265-8. PubMed ID: 23656522
[TBL] [Abstract][Full Text] [Related]
4. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in 'chemo-fog'/'chemo-brain'.
Raffa RB
J Clin Pharm Ther; 2010 Feb; 35(1):1-9. PubMed ID: 20175809
[TBL] [Abstract][Full Text] [Related]
5. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?
Raffa RB; Duong PV; Finney J; Garber DA; Lam LM; Mathew SS; Patel NN; Plaskett KC; Shah M; Jen Weng HF
J Clin Pharm Ther; 2006 Apr; 31(2):129-38. PubMed ID: 16635046
[No Abstract] [Full Text] [Related]
6. Clearing the air: a review of our current understanding of "chemo fog".
O'Farrell E; MacKenzie J; Collins B
Curr Oncol Rep; 2013 Jun; 15(3):260-9. PubMed ID: 23483375
[TBL] [Abstract][Full Text] [Related]
7. Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction.
Aluise CD; Sultana R; Tangpong J; Vore M; St Clair D; Moscow JA; Butterfield DA
Adv Exp Med Biol; 2010; 678():147-56. PubMed ID: 20738017
[TBL] [Abstract][Full Text] [Related]
8. Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.
Raffa RB
J Clin Pharm Ther; 2011 Aug; 36(4):437-45. PubMed ID: 21729110
[TBL] [Abstract][Full Text] [Related]
9. Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.
Wang XM; Walitt B; Saligan L; Tiwari AF; Cheung CW; Zhang ZJ
Cytokine; 2015 Mar; 72(1):86-96. PubMed ID: 25573802
[TBL] [Abstract][Full Text] [Related]
10. The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol.
Deleemans JM; Chleilat F; Reimer RA; Henning JW; Baydoun M; Piedalue KA; McLennan A; Carlson LE
BMC Cancer; 2019 Dec; 19(1):1243. PubMed ID: 31870331
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment.
Ren X; St Clair DK; Butterfield DA
Pharmacol Res; 2017 Mar; 117():267-273. PubMed ID: 28063894
[TBL] [Abstract][Full Text] [Related]
12. The (mis)classification of chemo-fog--methodological inconsistencies in the investigation of cognitive impairment after chemotherapy.
Shilling V; Jenkins V; Trapala IS
Breast Cancer Res Treat; 2006 Jan; 95(2):125-9. PubMed ID: 16261398
[TBL] [Abstract][Full Text] [Related]
13. Chemo fog: cancer chemotherapy-related cognitive impairment. Preface.
Raffa RB; Tallarida RJ
Adv Exp Med Biol; 2010; 678():vii-viii. PubMed ID: 20737998
[No Abstract] [Full Text] [Related]
14. Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment.
Myers JS; Pierce J; Pazdernik T
Oncol Nurs Forum; 2008 Nov; 35(6):916-20. PubMed ID: 18980922
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction.
Wardill HR; Mander KA; Van Sebille YZ; Gibson RJ; Logan RM; Bowen JM; Sonis ST
Int J Cancer; 2016 Dec; 139(12):2635-2645. PubMed ID: 27367824
[TBL] [Abstract][Full Text] [Related]
16. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.
Ferguson RJ; Ahles TA
Curr Neurol Neurosci Rep; 2003 May; 3(3):215-22. PubMed ID: 12691626
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives.
Cascella M; Di Napoli R; Carbone D; Cuomo GF; Bimonte S; Muzio MR
Recenti Prog Med; 2018 Nov; 109(11):523-530. PubMed ID: 30565571
[TBL] [Abstract][Full Text] [Related]
18. Neuroepidemiology of cancer and treatment-related neurocognitive dysfunction in adult-onset cancer patients and survivors.
Jean-Pierre P; McDonald BC
Handb Clin Neurol; 2016; 138():297-309. PubMed ID: 27637965
[TBL] [Abstract][Full Text] [Related]
19. Imaging as a means of studying chemotherapy-related cognitive impairment.
Raffa RB
Adv Exp Med Biol; 2010; 678():70-6. PubMed ID: 20738008
[TBL] [Abstract][Full Text] [Related]
20. Lost in the fog: understanding "chemo brain".
Hafner DL
Nursing; 2009 Aug; 39(8):42-5. PubMed ID: 19633502
[No Abstract] [Full Text] [Related]
[Next] [New Search]
